Vaginal estriol,
does it really help with Relief of vaginal dryness, pain, and dyspareunia in genitourinary syndrome of menopause?
research showsC. The 2024 AHRQ review rated improvement in vaginal dryness and dyspareunia from vaginal estrogen as low-certainty evidence, and more than half of the high-quality placebo-controlled trials found no significant dyspareunia benefit. Core outcomes are subjective symptoms, while pH and vaginal maturation are surrogates. Direct estriol-only evidence is thin, consisting mainly of a 172-person open noninferiority active-control trial and a 61-person placebo-controlled special-population trial; the class evidence also mixes estradiol and conjugated estrogens. Boundaries ① and ②-b impose the C ceiling, yielding 58 points.
ads claimIt is exaggerated to extend local GSM symptom relief to systemic menopause treatment, increased libido, or resolution of every urinary symptom. Results for estradiol and estriol products with different formulations and doses are not automatically interchangeable.
Useful facts when choosing a product
- Ovestin vaginal suppository is a prescription local estriol product, and any transition from initial dosing to a lower maintenance frequency should follow its labeling and the prescription.
- Action is primarily local but systemic absorption is not zero, so unexplained vaginal bleeding, a history of breast or endometrial cancer, and thrombotic risk require discussion before treatment.
- Vaginal irritation, discharge, or discomfort can occur, and persistent symptoms or bleeding require assessment for infection, dermatoses, malignancy, or another cause.
Chamgap Semantic Classification Code
Candidate index · review held
M.vaginal-estriol.vaginal.vaginal-dryness-pain-and-dyspareunia-in-genitourinary-syndrome-of-menopause.relieve.MULTIMedicinal interventions > Vaginal estriol > Vaginal > vaginal dryness, pain, and dyspareunia in genitourinary syndrome of menopause > Symptom-relief claim > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Danan 2024 reviewed 46 trials lasting at least eight weeks, including 22 vaginal-estrogen trials, and found possible improvement in dryness and dyspareunia versus placebo or no treatment, generally with low certainty. Garcia de Arriba 2022 randomized 172 women to 0.1% estriol cream or nonhormonal moisturizer; both markedly improved symptoms and dyspareunia over 43 days and moisturizer was noninferior. Hirschberg 2020 randomized 61 aromatase-inhibitor-treated breast-cancer patients and found ultra-low-dose estriol gel improved dryness, vaginal maturation, and pH versus placebo, but not the pain domain. Different formulations, doses, and populations should not be assumed to produce identical results for one suppository.
Why this is classified as C (58)
C. AHRQ rated dryness and dyspareunia improvement as low certainty, more than half of high-quality placebo-controlled trials were null for dyspareunia, and evidence centers on subjective symptoms plus pH and vaginal-maturation surrogates. Direct estriol-only evidence is limited to a 172-person active-control noninferiority trial and a 61-person special-population trial, while the class evidence mixes other estrogens, yielding the boundary ① and ②-b C ceiling with 58 points.
Counterpoint. Moisturizer or lubricant may be sufficient for mild symptoms, whereas persistent moderate-to-severe GSM can warrant a discussion of local estrogen benefits and individual risks.
Rejudgment record. Reassessment (cross-check reflected) — Applied the boundary ① and ②-b C ceiling because the 2024 AHRQ review rated benefit as low certainty, more than half of high-quality placebo-controlled trials were null for dyspareunia, outcomes centered on subjective symptoms and pH or vaginal-maturation surrogates, direct estriol evidence was limited to a 172-person noninferiority active-control trial and a 61-person special-population trial, and class evidence mixed other estrogens
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Relief of vaginal dryness and dyspareunia | C | Low-certainty class synthesis and limited direct estriol trials show improvement signals, but high-quality placebo-controlled findings are inconsistent. |
| Limited large-scale evidence for estriol alone | ? | Direct evidence is limited to a 172-person noninferiority active-control trial and a 61-person special-population trial, without large independent confirmation. |
| Extension of local effects to systemic menopausal symptoms | ? | No human efficacy evidence supports extending local vaginal estriol effects to systemic symptoms such as hot flashes or insomnia. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Danan ER et al. 2024 | Systematic review of randomized trials | 46 randomized trials, including 22 vaginal-estrogen trials | United States AHRQ and Veterans Affairs | Vaginal dryness, dyspareunia, most bothersome symptom, and adverse effects | Improvement in dryness and dyspareunia was low certainty, and more than half of high-quality placebo-controlled trials found no significant dyspareunia benefit. | Key independent synthesis |
| Garcia de Arriba S et al. 2022 | Multicenter open randomized active-controlled noninferiority trial | 172 postmenopausal women | Manufacturer of the nonhormonal moisturizer | Dryness, itching, burning, pain, and dyspareunia | Both estriol and moisturizer improved symptoms substantially, and moisturizer was noninferior. | Direct estriol comparative evidence |
| Lindén Hirschberg A et al. 2020 | Randomized double-blind placebo-controlled phase 2 trial | 61 women with breast cancer receiving aromatase inhibitors | Italfarmaco | Dryness, pain, vaginal maturation, pH, and sexual function | Dryness and objective measures improved, but the sexual-function pain domain did not. | Small direct placebo-controlled evidence |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-20).
Final verification and publication gate: Codex · Evidence date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Vaginal estriol x relief of GSM dryness, pain, and dyspareunia — Evidence Grade C·58. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/vaginal-estriol-gsm-dryness-pain-dyspareunia/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.